“FLOW Trial: Semaglutide and 24% Fewer Kidney Events The First Dedicated GLP-1 Kidney-Outcomes Trial in Type 2 Diabetes and CKD”. 2026. Diabzen 4 (20): 40-41. https://thediabzen.com/index.php/d/article/view/63.